Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MoonLake Immunotherapeutics filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing sonelokimab (SLK) for inflammatory diseases. Form 8-K reports cover operating and financial results, clinical-trial disclosures for SLK programs, FDA meeting updates, Regulation FD communications, material agreements and capital-structure matters involving Class A ordinary shares.
Proxy materials describe annual meeting voting matters, including director elections, auditor ratification, executive compensation and amendments to the 2022 Equity Incentive Plan. The filing record also includes exhibits and registration-related disclosures tied to financings, governance matters and shareholder approvals.
MoonLake Immunotherapeutics reported an equity award to a senior executive. Chief Scientific Officer Kristian Reich filed a Form 4 showing a grant of stock options covering 520,342 Class A ordinary shares at an exercise price of $11.29 per share.
The options were granted on January 7, 2026 and vest in four equal annual installments on January 7, 2027, 2028, 2029, and 2030, as long as he continues to serve the company through each vesting date. Following this grant, he holds 520,342 derivative securities directly.
MoonLake Immunotherapeutics reported that it received positive feedback from the U.S. Food and Drug Administration on the clinical evidence strategy for its drug candidate Sonelokimab (SLK) in hidradenitis suppurativa, following a requested Type B FDA meeting. This feedback relates to how the company is generating the clinical data needed to support SLK in this indication.
The company also plans to hold an Investor Day on February 23, 2026 at 8:00 a.m. Eastern Time to discuss the outcomes of the Type B FDA meeting in more detail and to present new clinical data for SLK across multiple indications. A press release with these updates was filed as an exhibit to this report.
MoonLake Immunotherapeutics entered an underwriting agreement to sell 7,142,857 Class A ordinary shares at $10.50 per share. The transaction is expected to generate gross proceeds of $75 million before underwriting discounts and offering expenses.
The shares are being issued under an effective Form S-3 shelf (File No. 333-274286), with a prospectus supplement dated November 5, 2025. Closing is expected on November 6, 2025, subject to customary closing conditions. The company agreed to customary indemnification provisions in favor of the underwriter, Leerink Partners LLC.
MoonLake Immunotherapeutics is offering 7,142,857 Class A Ordinary Shares at $10.50 per share pursuant to a prospectus supplement. The company estimates net proceeds of approximately $72.6 million after underwriting discounts and offering expenses, to be used to fund research and development of SLK and for general corporate purposes. The company expects these funds, together with existing cash and investments, to be sufficient to fund its planned Phase 3 clinical trial in PPP.
Gross proceeds are $74,999,999, with underwriting discounts and commissions of $2,250,000. Shares outstanding were 64,230,722 as of September 30, 2025, and are expected to be 71,373,579 after this offering. New investors will experience immediate dilution of $5.40 per share based on the as adjusted net tangible book value as of September 30, 2025. A 60‑day lock‑up applies to the company, directors, officers and certain holders. MLTX last traded at $10.13 on November 4, 2025. Leerink Partners is the sole bookrunning manager, with delivery expected on or about November 6, 2025.
MoonLake Immunotherapeutics reported third-quarter 2025 results showing higher R&D investment and a wider loss as it advances sonelokimab. R&D expenses were $60.6M and total operating expenses reached $71.4M, leading to a net loss of $70.7M for the quarter and $167.3M year-to-date. Interest expense was $3.2M, reflecting new debt.
Liquidity remains strong with cash and cash equivalents of $350.7M and short‑term marketable securities of $29.7M. Management states this resources base funds operations into the second half of 2027. Shareholders’ equity was $288.9M, and long‑term debt stood at $73.7M following a $75M initial draw under a $500M credit facility.
Clinical progress was mixed: the company announced that VELA‑1 met its primary endpoint in hidradenitis suppurativa, while a higher‑than‑expected placebo response prevented VELA‑2 from meeting its pre‑specified primary endpoint. As a result, the company did not achieve certain loan milestones tied to additional tranches under the facility.
MoonLake Immunotherapeutics furnished an 8-K announcing a press release with its financial results for the quarter ended September 30, 2025 and clinical program updates. Under Item 2.02, the company reported Q3 2025 results via Exhibit 99.1. Under Item 7.01, it highlighted results from the Phase 2 LEDA trial of Sonelokimab (SLK) in adult palmoplantar pustulosis and an interim analysis from the Phase 3 VELA-TEEN trial in adolescents with hidradenitis suppurativa. The Item 7.01 information is being furnished and is not deemed filed under Section 18.
Insider purchase by MoonLake Immunotherapeutics CFO. The filing shows Matthias Bodenstedt, the company’s Chief Financial Officer and a director, purchased 10,870 Class A ordinary shares on 10/08/2025 at a weighted average price of $9.09 per share. After the transactions he beneficially owns 627,536 shares. The filing notes the shares were bought in multiple trades at prices ranging from $9.085 to $9.091244 and that the weighted average price is reported. The signature date is 10/09/2025.
MoonLake Immunotherapeutics - Schedule 13G/A summary: This filing reports that Bihua Chen, acting through Cormorant Asset Management-related funds, beneficially owns 1,994,173 Class A Ordinary Shares, representing 3.14% of the outstanding Class A shares. The holder reports shared voting and dispositive power over these shares and no sole voting or dispositive power. The percentage calculation references the issuer's reported outstanding Class A share count of 63,501,402. The filer certifies the securities are held in the ordinary course of business and not to influence control of the issuer.
MoonLake Immunotherapeutics reported that it has released week 16 results from its Phase 3 VELA-1 and VELA-2 trials, which are part of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin disease. These late-stage studies are important because they test whether the company’s therapy can provide meaningful benefit in a difficult-to-treat population.
The company issued a press release with the data on September 28, 2025 and scheduled a webcast on September 29, 2025 at 8:00 a.m. Eastern Time to review the results. The press release detailing the clinical data has been filed as an exhibit to this report, giving investors and clinicians access to the full outcome of the VELA-1 and VELA-2 trials.
Kristian Reich, Chief Scientific Officer and director of MoonLake Immunotherapeutics (MLTX), executed an equity exchange on 09/02/2025. He surrendered 1,456 common shares of MoonLake AG in exchange for 48,978 Class A ordinary shares of the issuer, and as part of the transaction 48,978 Class C ordinary shares were automatically cancelled for no consideration. The filing discloses that 10,000 MoonLake AG shares held by the reporting person remain subject to a reverse-vesting schedule that completes on January 18, 2026. The filing also states that JeruCON Beratungsgesellschaft mbH owns 2,974,551 Class A ordinary shares, of which Dr. Reich may be deemed an indirect beneficial owner.